Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2026-02-22 @ 5:23 PM
Study NCT ID:
NCT05394233
Status:
UNKNOWN
Last Update Posted:
2022-05-27
First Post:
2022-05-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Sponsor:
Sichuan Cancer Hospital and Research Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
BAT1706-LJ2022
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None